Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dronabinol
- Development stage
- Approved
- Lead developer
- Unimedco
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dronabinol is a synthetic (man-made) form of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. It acts as an agonist at cannabinoid receptors in the central nervous system, primarily targeting the CB1 receptor. Dronabinol is used to treat nausea and vomiting associated with chemotherapy in patients who have not responded adequately to conventional antiemetic treatments. It is also indicated for anorexia and weight loss in patients with acquired immunodeficiency syndrome (AIDS). The drug exerts its effects by modulating neurotransmitter release through activation of cannabinoid receptors, thereby influencing appetite stimulation and suppression of nausea and vomiting[1][2][3][4][5][6][7][8].
- Brand names
- MarinolSyndros
- Other names
- tetrahydrocannabinolTHC
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on dronabinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dronabinol.